Lifestance Health Group approves new $100 mln share repurchase program

LifeStance Health Group, Inc. (Nasdaq: LFST) has announced the approval of a $100 million share repurchase program by its Board of Directors. This initiative allows the company to repurchase up to $100 million of its outstanding common stock, with the flexibility to execute repurchases in the open market or through privately negotiated transactions, including accelerated share repurchase programs, subject to market conditions.

The share repurchase program reflects LifeStance’s strong cash generation and healthy balance sheet, as highlighted by its recent financial performance. For the full year 2025, the company reported revenue of $1,424.3 million, representing a 14% increase compared to the prior year. Additionally, LifeStance generated $146.2 million in cash flow from operations and $110.0 million in Free Cash Flow.

The company also provided 2026 guidance, expecting full-year revenue to range between $1.615 billion and $1.655 billion, with Adjusted EBITDA projected between $185 million and $205 million. These figures underscore the company’s commitment to long-term growth while returning capital to shareholders.

The repurchase program is part of LifeStance’s broader capital allocation strategy, which includes continued investment in growth initiatives and maintaining a strong financial position. The company ended the fourth quarter of 2025 with $248.6 million in cash and $265.9 million in net long-term debt.

This move follows a year of significant operational and financial progress, including a 9% increase in its clinician base to 8,040 clinicians and a 14% increase in visit volumes to 9.0 million for the full year 2025. The share repurchase program is expected to enhance shareholder value by reducing the number of outstanding shares, potentially increasing earnings per share and improving overall capital efficiency.